The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

24 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
1
Piceatannol, a natural trans-stilbene compound, inhibits human glyoxalase I.EBI
Tokyo University of Science
113
The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules.EBI
Uniroyal Chemical
7
Novel bivalent inhibitors with sub-nanomolar affinities towards human glyoxalase I.EBI
Chengdu University
2
Inhibition by active site directed covalent modification of human glyoxalase I.EBI
University of Maryland
7
Synthesis and evaluation of alpha-hydroxythiol esters as antitumor agents and glyoxalase I inhibitors.EBI
TBA
18
Design and evaluation of azaindole-substituted N-hydroxypyridones as glyoxalase I inhibitors.EBI
Chugai Pharmaceutical
9
S-(N-aryl-N-hydroxycarbamoyl)glutathione derivatives are tight-binding inhibitors of glyoxalase I and slow substrates for glyoxalase II.EBI
University of Maryland
5
Discovery of a new type inhibitor of human glyoxalase I by myricetin-based 4-point pharmacophore.EBI
Tokyo University of Science
7
Structural investigation into the inhibitory mechanisms of indomethacin and its analogues towards human glyoxalase I.EBI
Sun Yat-Sen University
31
Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies.EBI
Sun Yat-Sen University
4
Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I.EBI
Tokyo University of Science
6
Structure-activity relationship of human GLO I inhibitory natural flavonoids and their growth inhibitory effects.EBI
Tokyo University of Science
3
NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family.EBI
Johann Wolfgang Goethe University
1
Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I.EBI
Keio University
16
Addition of hydrophobic side chains improve the apoptosis inducibility of the human glyoxalase I inhibitor, TLSC702.EBI
Tokyo University of Science
26
Design, synthesis and biological evaluation of novel glyoxalase I inhibitors possessing diazenylbenzenesulfonamide moiety as potential anticancer agents.EBI
Jordan University of Science and Technology
7
4-Amino-1,2,4-triazole-3-thione-derived Schiff bases as metallo-β-lactamase inhibitors.EBI
University of Montpellier
3
Induction of enantio-selective apoptosis in human leukemia HL-60 cells by (S)-erypoegin K, an isoflavone isolated from Erythrina poeppigiana.EBI
Meijo University
11
Role of hydrophobic interactions in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active site of the antitumor target enzyme glyoxalase I.EBI
University of Maryland
15
Recent advances in the discovery and development of glyoxalase I inhibitors.EBI
Chengdu University
2
Synthesis and activity of gamma-(L-gamma-azaglutamyl)-S-(p-bromobenzyl)-L-cysteinylglycine: a metabolically stable inhibitor of glyoxalase I.EBI
University of Minnesota
63
Metal-Binding Pharmacophore Library Yields the Discovery of a Glyoxalase 1 Inhibitor.EBI
TBA
5
Syntheses and kinetic evaluation of hydroxamate-based peptide inhibitors of glyoxalase I.EBI
University of Waterloo
98
MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOFBDB
Suzhou Langrui Biopharmaceutical